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Abstract
Purpose We developed a pharmacokinetic model of intravenous sildenafil in newborns with congenital diaphragmatic hernia
(CDH) to achieve a target plasma concentration of over 50 μg/l.
Methods Twenty-three CDH newborns with pulmonary hypertension (64 blood samples) received intravenous sildenafil.
Patients received a loading dose of 0.35 mg/kg (IQR 0.16 mg/kg) for 3 h, followed by a continuous infusion of 1.5 mg/kg/
day (IQR 0.1 mg/kg/day). For model development, non-linear mixed modeling was used. Inter-individual variability (IIV) and
inter-occasion variability were tested. Demographic and laboratory parameters were evaluated as covariates. Normalized pre-
diction distribution errors (NPDE) and visual predictive check (VPC) were used for model validation.
Results A two-compartment disposition model of sildenafil and a one-compartment disposition model of desmethyl sildenafil
(DMS) was observed with IIV in sildenafil and DMS clearance and volume of distribution of sildenafil. NPDE and VPC revealed
adequate predictability. Only postnatal age increased sildenafil clearance. This was partly compensated by a higher DMS
concentration, which also has a therapeutic effect. In this small group of patients, sildenafil was tolerated well.
Conclusions This model for sildenafil in CDH patients shows that concentration-targeted sildenafil dosing of 0.4 mg/kg in 3 h,
followed by 1.6 mg/kg/day continuous infusion achieves appropriate sildenafil plasma levels.
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What is already known about this subject:
- Therapy resistant pulmonary hypertension (PH) in congenital diaphrag-
matic hernia (CDH) patients has a high mortality rate.
- Sildenafil is used for the treatment of PH, but data on optimal dosing and
pharmacokinetics (PK) are lacking.
- In this study, we developed a PK model for sildenafil in CDH patients.
What this study adds:
- An intravenous sildenafil loading dose of 0.4 mg/kg in 3 h followed by
continuous infusion of 1.6 mg/kg/day achieves therapeutic sildenafil
plasma levels in CDH patients in approximately 1 h.
- The current PK model is the first step toward concentration range
targeted sildenafil dosing in CDH patients.
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Introduction
Congenital diaphragmatic hernia (CDH) is a developmental
defect of the diaphragm with abnormal lung development and
pulmonary vasculature growth, resulting in pulmonary hyper-
tension (PH) [1]. CDH is associated with a reported mortality
of approximately 27% in live-born patients since the imple-
mentation of international treatment guidelines [2–4]. PH is
one of the most important risk factors for poor outcome in
infants with CDH [1, 5, 6].
During fetal life, high resistance in the pulmonary circu-
lation is normal and causes most of the blood flow to bypass
the lungs through the ductus arteriosus. As part of normal
transition, the pulmonary vascular resistance drops imme-
diately after birth and the blood flow through the lung vas-
culature increases significantly. Normal values of pulmo-
nary vascular pressures, similar to healthy adults, are usual-
ly reached around the age of 2 months [7]. In infants with
CDH, the pulmonary vascular resistance often does not drop
adequately, due to increased vascular reactivity, excessive
muscularization of the pulmonary arterioles, and increased
thickness of the arterial media and adventitia [8].
Intravenous sildenafil, a phosphodiesterase 5 (PDE5) in-
hibitor that increases cyclic guanosine monophosphate
(cGMP) resulting in pulmonary vasodilation, is increasing-
ly used in infants with CDH, with promising results [9–11].
In newborns with persistent pulmonary hypertension of the
newborn (PPHN) without CDH, sildenafil improves oxy-
genation index (OI) and survival [12]. However, data on
optimal dosing, pharmacokinetics (PK), and dynamics are
scarce in newborns, and CDH patients are often excluded
from trials. PK of intravenous sildenafil in term neonates
with PPHN, using a two-compartment model, shows a
threefold increase in sildenafil clearance and its active me-
tabolite, desmethyl sildenafil (DMS), in the first week of life
[13]. DMS has a 50% potency compared to sildenafil [14].
Volume of distribution was fourfold higher than in adults,
resulting in a longer half-life [13].
Also, long-term safety data are scarce [15]. In a study eval-
uating safety using a dose-escalating strategy, intravenous sil-
denafil was well tolerated and it improved oxygenation when
using a higher infusion dose. With a 3-h loading dose of 0.4
mg/kg and a continuous infusion of 1.6 mg/kg/day, target
plasma concentration was achieved without causing hypoten-
sion [16].
As PH is a major determent of survival in patients with
CDH, data on the PK and pharmacodynamics of sildenafil
are urgently needed. The objective of this study was to devel-




This open-label study was conducted in two level-3 referral
centers for CDH in Germany and the Netherlands between
November 2013 and September 2015. Local ethical review
boards approved the protocol. Twenty-three newborns with
CDH and clinical signs of PH were treated with intravenous
sildenafil. Patients received a loading dose of 0.35 mg/kg
(IQR 0.16 mg/kg) for 3 h, followed by a continuous infusion
of 1.5 mg/kg/day (IQR 0.1 mg/kg/day). However, many dif-
ferent regimens were being used; ten patients received a load-
ing dose of 0.4 mg/kg in 3 h, followed by continuous infusion
of 1.6 mg/kg/day; in one patient, the infusion was very slowly
increased over time, starting with 0.2 mg/kg/day, in others no
loading dose was given and a continuous infusion was started,
ranging from 1.4 to 4 mg/kg/day. Target plasma sildenafil
levels over 50 μg/l were aimed for, assuming that the same
target range is applicable in CDH patients compared to other
causes of neonatal PH [16]. DMS was not added to calculate
this target range because the target range for DMS is unknown
and DMS was also not taken into account in the study of
Steinhorn et al. [16]. The patients were treated as per protocol
according to international consensus [3]. Patient and baseline
characteristics of the 23 patients are provided in
Supplementary Table 1. All patients received inotropic drug
support and were treated with inhaled nitric oxide (iNO). One
patient started treatment with bosentan in the second week of
life. Thirteen patients needed extracorporeal membrane oxy-
genation (ECMO) (median time of start 8:15 h after birth, IQR
9:39 h), of whom two were already on ECMO before silden-
afil initiation, overall mortality was 26%.
Primary outcomes were the PK of sildenafil and its active
metabolite, DMS. Safety data were collected as secondary
outcome variables. Oxygenation index (OI) was used to eval-
uate the clinical effect of sildenafil on PH. Hypotension was
defined as mean blood pressure lower than gestational age in
weeks. The Vasoactive inotropic score (VIS) was used to eval-
uate cardiovascular tolerance. This is a scoring system used
for the amount of inotropic support needed and is negatively
associated with long-term outcome [17]. OI and VIS were
analyzed using linear regression analysis.
Laboratory analysis
We used 50 μl EDTA blood and 200 μl internal standard
solution (vardenafil in methanol) was added. This solution
was vortexed for 10 s and centrifuged for 5 min. A supernatant
of 200 μl was added to the insert vial, which was used in the
Eur J Clin Pharmacol
Thermo TQS Vantage LC-MS/MS. Column 2.1 × 100 mm
Waters Acquity CSH C18 1.7 um. The mobile phase A
consisted of 2 mM ammonium acetate in 0.1% formic acid
in water. The mobile phase B consisted of 2 mM ammonium
acetate in 0.1% formic acid in LC-MS methanol. Flow rate
was 0.5 ml/min. The mobile phase composition changed lin-
early during analysis in a percentage mobile phase A (from 80
to 0%) and B (from 2 to 100%). Total analysis time was 4 min.
The injected volume was 10 μl. The method was validated
according to FDA guidelines between 2–1000 μg/l for silden-
afil and 2–500 μg/l for DMS [18].
Population PK modeling
PK analysis was conducted with non-linear mixed-effects
model ing using NONMEM® version 7.2 (ICON
Development Solutions, Ellicott City, MD) and PsN® (ver-
sion 3.7.6). Pirana software was used as an interface between
NONMEM, R (version 3.2.2) and Xpose (version 4). Using
NONMEM, we could estimate average PK parameters for the
population as well as inter-individual variability (IIV), inter-
occasion variability (IOV), and residual error.
Base model development
One- two- and three-compartment models were tested for sil-
denafil and DSM, using the first-order conditional estimation
method with interaction (FOCE+I). First, a structural model
for sildenafil was developed. IIV and IOV, with occasion de-
fined per day, were assessed on each parameter using an ex-
ponential model. Residual variability was first tested with an
additive and proportional error for each component. The pa-
rameters for the base model for sildenafil were fixed when the
model for the metabolite was developed. In the combined
model, we estimated all parameters.
Model selection was based on minimum objective function
values, parameter precision, error estimates, shrinkage values,
and visual inspection of the goodness of fit plots. Shrinkage
was calculated for all model parameters. A shrinkage value
below 20% was considered acceptable [19].
Covariate model development
Demographic and laboratory characteristics including post-
natal age, gender, creatinine, urea, aspartate transaminase
(ASAT), and alanine transaminase (ALAT) were evaluated
as potential model covariates. Allometric scaling was used
to account for variability in PK parameters owing to differ-
ences in bodyweight [20]. Covariates that significantly im-
proved the model in univariate analysis, defined as p ≤ 0.05,
were added to the full model. A backward elimination pro-
cess was subsequently performed with statistical signifi-
cance indicated by p ≤ 0.001. Continuous covariates were
normalized to the population median values and incorporat-
ed as power model functions (Eq. 1). Categorical covariates
were transformed to binary covariates and incorporated as
shown in Eq. 2.
θi ¼ θpop* covicovm
 θcov
ð1Þ
θi ¼ θpop*θcovcovi ð2Þ
With θi being the individual model predicted PK parameter
(e.g., clearance) for an individual with covariate value covi,
θpop being the population estimate for that parameter, covm
representing the median covariate value and θcov the covari-
ate effect. In the equation for categorical covariates, covi is
either 1 or 0.
Model evaluation
We used multiple procedures to assess the robustness of the
parameter estimates and to validate the final model. First of
all, a bootstrap resampling method was applied [21].
Thousand bootstrap datasets were generated by sampling ran-
domly from the original dataset with replacement. The validity
of the model was evaluated by comparing the median values
and their corresponding 95% confidence intervals of the boot-
strap replicates with the estimates of the original dataset.
Subsequently, the model was validated using both visual
predictive check (VPC) by simulating 500 datasets and a nor-
malized prediction distribution errors (NPDE) analysis [22,
23]. The VPCs were prediction corrected and stratified for
the covariates that are included in the final model. NPDE is
a simulation-based diagnostic that can be used to evaluate
models developed on datasets with variable dosing regimens.
The analytical value of this method has been previously de-
scribed by Comets et al. [23].
Concentration effect relationship
Drug concentrations were simulated on the time points of
blood pressure measurement to find a relationship between
the concentration of sildenafil, DMS, and hypotension (mean
blood pressure lower than gestational age), assuming a 50%
activity of DMS compared with sildenafil. The relationship
was tested using Mann-Whitney statistical testing.
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Results
Sixty-four samples were taken at different time points between
1 and 385 h after the start of the infusion, 34 of these samples
were taken during ECMO. None of the patients received
hemofiltration.
Median sildenafil level of all patients was 200 (range 42–
262) μg/l at 3 h and increased to 366 (19–506) μg/l at 12 h.
Infants receiving a loading dose of 0.4 mg/kg in 3 h achieved
sildenafil levels ranging between 190 and 262 μg/l at 3 h and
between 346 and 506 μg/l after 12 h.
Median DMS level within the first 12 h was 20 (range 9–
85) μg/l with a slow increase to a median of 65 (range 17–92)
μg/l between 24 and 48 h.
To evaluate the effect of sildenafil on OI and VIS, numbers
were too small. However, in only one patient, sildenafil infu-
sion was temporarily stopped after 1 h due to hypotension that
could not be sufficiently treated with inotropes. One patient
had two episodes of hypotension, after 7 h and 7 days, for
which the sildenafil was decreased for the same reason. This
patient also developed pulmonary hemorrhage after 6 days of
sildenafil infusion. In both patients, no correlation with high
sildenafil levels was seen. No other adverse events were seen.
Base model and covariate analysis
The model included two-compartment disposition of sildena-
fil and one-compartment disposition of DMS with IIV in both
clearance of sildenafil and DMS, and in volume of distribution
of sildenafil. The residual error was described with a propor-
tional error model. Allometric scaling with fixed exponents
(0.75 CL and Q and 1 for Vd) improved the model. Estimation
of the exponent did not result in further improvement.
The base two-compartment model with allometric scaling
was used as reference for the covariate analysis. After graph-
ical analysis, the univariate analysis resulted in the following
covariates: ECMO, postnatal age, urea, ALAT, and weight.
With a median age of 2.4 days, postnatal age was the only
significant covariate after backward elimination. Increase in
age resulted in increased sildenafil clearance, as can be seen in
Fig. 1. Age is presented in 3 groups: 2, 6 and 10 days. When
age increases, the clearance highly increases. If age is in-
creased from 2.4 to 10 days, clearance is increased with a
factor of 4 (Table 1). Shrinkage (residual error in the model)
is good with regards to clearance. Shrinkage is high for distri-
bution volume, resulting in a large residual error.
Evaluation of the final model
All estimates were within the limits, given the criteria as de-
fined. Goodness-of-fit plots of the final model showed that the
population predictions and individual predictions were evenly
distributed around the line of unity when compared with ob-
served concentrations, and the conditional weighted residuals
were normally distributed over time (Fig. 2). A bootstrap anal-
ysis with 1000 bootstrap replicates was performed to obtain
95% confidence intervals for all PK parameters.
Owing to minimization and boundary errors, the bootstrap
results were recomputed without filtering the samples (1000
runs computed: 495 runs successful). Results of the bootstrap
are shown in Table 1.
In the VPC, a large variation was present. However, the
median and the variability were within the corresponding sim-
ulations (Fig. 3). This demonstrates the good predictive per-
formance of the final model in the internal validation.
Evaluation of the predictive performance with NPDE analysis
showed adequate predictive ability, with distribution of the
NPDEs not significantly deviating from a normal distribution
(Figure 4 in the supplement).
Concentration effect relationship
To investigate the relationship between blood pressure and
drug concentration, simulations of drug concentrations were
Fig. 1 Simulation of the current
dose in which 0.4 mg/kg was
given in 3 h, followed by 1.6
mg/kg/day. This leads to
concentrations within the
therapeutic range. However, in
the group with the youngest age
(2 days), the concentration is in
higher target range. The
therapeutic range of 50–300 ug/l
is marked in yellow
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performed on the time points of blood pressure measurement.
No correlation was seen.
Discussion
Although intravenous sildenafil is increasingly used in CDH
patients, a structured analysis of PK data was lacking.
Therefore, the objective of the study was to develop a PK
model and dosing regimen for intravenous sildenafil in new-
borns with CDH. A loading dose of 0.4 mg/kg in 3 h followed
by continuous infusion of 1.6 mg/kg/day achieves target sil-
denafil plasma levels within 3 h.
Only 5 RCTs with a total of 166 patients have evaluated the
effect of sildenafil in newborns, all excluding patients with
congenital anomalies, including CDH. When sildenafil was
compared with placebo or MgSO4, a decrease in OI and mor-
tality was seen. When sildenafil was added to inhaled NO,
there was no difference in outcome [24–28]. In CDH patients,
only retrospective data are available. A decrease in pulmonary
vascular resistance index and an increase in cardiac output
were found in a small group of oral sildenafil-treated infants
with CDH refractory to iNO [9]. However, there is a large
interpatient variability in pharmacokinetics of oral sildenafil
[29]. Intravenous sildenafil in CDH patients was associated
with improved OI and the reversal of the right-to-left shunt
ratio over the ductus arteriosus. However, a significant in-
crease in vasopressor support was also observed [10, 30].
We found that postnatal age increases sildenafil clearance
suggesting maturation of the expression of hepatic CYP
enzymes involved, as also observed by Mukherjee et al.
Sildenafil metabolism is mostly mediated by two enzymes;
CYP3A4 and CYP2C9 [31]. The activity of both enzymes is
very low at birth and increases substantially during the first
weeks of life [32–34]. Also, the improvement of the clinical
condition possibly increases the metabolic activity of the liver
[32, 35, 36]. The increase in clearance shows a non-linear
increase over time and is stronger in younger age as common-
ly seen in infants [13, 35]. This increase in clearance lowers
sildenafil plasma levels which are partly compensated with the
increase of DMS concentrations in time (Figures 1 and 5 in the
supplement).
A loading dose of 0.4 mg/kg in 3 h followed by continuous
infusion achieved target sildenafil plasma levels within 3 h
(Fig. 1). This dosing regime was first described by Steinhorn
et al. in a dose-escalating trial in newborns with PPHN in the
absence of CDH. Is this small group of 4 patients, sildenafil
plasma levels reached 107.78 μg/l at 3 h and 246.28 μg/l at 24
h, and it was well tolerated and improved the OI [16]. Our data
suggest that there is no major difference in the PK of sildenafil
in CDH patients, although our patients reached therapeutic
plasma levels earlier, after approximately 1 h. As the clinical
condition of CDH patients can deteriorate quickly, the ideal
dosing regimen reaches therapeutic plasma levels as soon as
possible with the least possible side effects. This seems feasi-
ble with the dosing regimen we propose. Evaluation of the
clinical effects of sildenafil and DMS in CDH patients sug-
gested relative cardiovascular tolerance but a more clear effect
could not be seen. With the amount of patients and samples,
we could develop a PK model, however, for the secondary
Table 1 Parameter estimates of
the base model, final model, and
bootstrap analysis
Base model Final model (rse I %) Bootstrap results
Median [95% CI]
OFV 1191 1160 1154 [918–1372]
CL sildenafil (L/h) 6.7 5.2 (19) 5.1 [3.7–7.0]
Age*(days) 0.58 (26) 0.58 [0.3–0.9]
V1 sildenafil (L) 75.1 115 (30) 118 [61–159]
V2 sildenafil (L) 10 10 (na) NA
Q sildenafil (L/h) 44.3 221 (3) 330 [1.9–13719]
Cl metabolite (L/h) 24.2 25.9 (12) 26.6 [21.2–32.6]
V3 metabolite 1040 366(83%) 287 [79–999]
IIV (%)
Cl sildenafil 50.3 51.3 (24%) 24 [5–65]
V1 sildenafil 32.2 21.0 (55%) 5 [0–35]
Cl metabolite 37.8 40.5 (25%) 15 [2–51]
Residual variability
Proportional Cl sildenafil 0.60 0.50 (10) 0.5 [0.4–0.6]
Proportional metabolite 0.57 0.44 (10) 0.4 [0.4–0.5]
*Cl = Cl (sildenafil)*(weight in kg/70)**0.75*EXP(IIV sildenafil)*(AGE/2.4)**0.58,
Shrinkage: Base model Cl sildenafil 12%, Cl metabolite 26%, V1 61%; final model Cl sildenafil 11%, V1 59 %,
and Cl metabolite 19%
Eur J Clin Pharmacol
outcome, parameter numbers were too low. Also, 57% of pa-
tients needed ECMO treatment, at that point making the OI
invalid to analyze the effect of sildenafil on PH. As these are
retrospective data, echocardiography was not performed at
predefined time points, making it impossible to evaluate the
effect of sildenafil on PH in these patients. However, in this
selected group of critically ill CDH patients, PH mortality was
26%, whereas reported overall mortality for CDH patients is
27%.
There are some limitations of the study. As CDH is a
rare disease, 23 patients is a relatively large group, but to
test the model and to better achieve patient targeted dos-
ing, prospective external validation is needed. A multicen-
ter RCT, the CoDiNOS trial, has started in Europe, com-
paring iNO with intravenous sildenafil as first-line treat-
ment of PH in CDH patients (NTR6982). In this trial,
sildenafil and DMS plasma levels will be collected to
externally validate the model.
Fig. 2 Goodness of fit plots. Goodness-of-fit plots of the final model. a
Observed concentration (DV) plotted against predicted concentration
(PRED). b DV plotted against individual predicted concentration
(IPRED). c Conditional weighted residuals versus time after start. d
Conditional weighted residuals versus age
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We were not able to retain a significant effect of ECMO on
our model. However, considering the increase in circulating
volume and the use of an oxygenator, one would assume
ECMO to be of substantial influence [37, 38]. We probably
did not find this due to the relatively few samples taken in only
23 patients.We observed both lowered sildenafil levels as well
as increased levels when on ECMO. Ahsman et al. evaluated
the PK of oral sildenafil in infants on ECMO and post-ECMO
and also found contradicting results on the influence of
ECMO [29, 39]. In comparison to the work of Ahsman, new
ECMO systems are used with smaller tubes and filters. We
expect that the effect of ECMO can be better evaluated as part
of the external validation performed in the CoDiNOS trial
(NTR6982). Bosentan is known to decrease sildenafil plasma
concentrations, but it was not a significant covariate in our
study because only one patient was co-treated with bosentan
[40]. Sildenafil loading dose and continuous infusion seem to
be tolerated well as in only two patients sildenafil had to be
temporarily decreased or interrupted due to hypotension.
However, because of the retrospective character of the study,
Fig. 3 Visual predictive check of sildenafil (CMT/compartment 1) and
DMS (CMT/compartment 3), showing how well the average trend of the
observations (solid line) and how well the variability of the observed data
(two dashed lines) fall within the model-simulated average trend (red
shaded area) and the model-simulated variability (blue shaded areas)
represented as a 95% confidence interval (CI). The average and the
variability of the observed data both fall within the corresponding
simulations
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further analysis of the cardiovascular tolerance of sildenafil in
this patient group, using VIS, was not possible. Kipfmueller
et al. found an acute improvement of OI but also the needs to
increase inotropic support in patients with CDH [30]. In a
prospective setting, these secondary outcome parameters can
be evaluated much more reliable.
This is the first study on the PK of intravenous sildenafil in
a representative population of CDH patients in need for PH
treatment. Using population PK modeling, a sildenafil plasma
concentration model was developed with sparse sampling. In
conclusion, intravenous sildenafil loading dose of 0.4 mg/kg
for 3 h followed by continuous infusion of 1.6 mg/kg/day
achieves adequate sildenafil plasma levels. Only postnatal
age influences its clearance. This dosing regimen was well
tolerated in this small group of CDH patients. The current
PK model is the first step toward concentration targeted sil-
denafil dosing in CDH patients. The model will be further
validated in the CoDiNOS trial (NTR6982).
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